JP2017537892A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537892A5 JP2017537892A5 JP2017523286A JP2017523286A JP2017537892A5 JP 2017537892 A5 JP2017537892 A5 JP 2017537892A5 JP 2017523286 A JP2017523286 A JP 2017523286A JP 2017523286 A JP2017523286 A JP 2017523286A JP 2017537892 A5 JP2017537892 A5 JP 2017537892A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- agent
- cancer
- activity
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 34
- 239000005557 antagonist Substances 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 31
- 229940122315 Notch pathway inhibitor Drugs 0.000 claims description 30
- 108700041286 delta Proteins 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 239000002955 immunomodulating agent Substances 0.000 claims description 25
- 108010070047 Notch Receptors Proteins 0.000 claims description 23
- 102000005650 Notch Receptors Human genes 0.000 claims description 23
- 229940044551 receptor antagonist Drugs 0.000 claims description 22
- 239000002464 receptor antagonist Substances 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 230000002708 enhancing effect Effects 0.000 claims description 10
- 239000000556 agonist Substances 0.000 claims description 8
- 102000002698 KIR Receptors Human genes 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 5
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 4
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 4
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 4
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 102000017578 LAG3 Human genes 0.000 claims description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 4
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 230000009464 antigen specific memory response Effects 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 210000003289 regulatory T cell Anatomy 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 230000002459 sustained effect Effects 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 229940123494 CD20 antagonist Drugs 0.000 claims description 2
- 229940121697 CD27 agonist Drugs 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 229940123205 CD28 agonist Drugs 0.000 claims description 2
- 229940123189 CD40 agonist Drugs 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 229940123828 CD80 antagonist Drugs 0.000 claims description 2
- 229940121850 CD86 agonist Drugs 0.000 claims description 2
- 229940121764 CD86 antagonist Drugs 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 101000978766 Homo sapiens Neurogenic locus notch homolog protein 1 Proteins 0.000 claims description 2
- 101000577199 Homo sapiens Neurogenic locus notch homolog protein 2 Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229940124060 PD-1 antagonist Drugs 0.000 claims description 2
- 229940123751 PD-L1 antagonist Drugs 0.000 claims description 2
- 229940121678 PD-L2 antagonist Drugs 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 229940123803 TIM3 antagonist Drugs 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 102000044457 human DLL4 Human genes 0.000 claims description 2
- 102000045609 human NOTCH1 Human genes 0.000 claims description 2
- 102000046883 human NOTCH2 Human genes 0.000 claims description 2
- 102000058223 human VEGFA Human genes 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 210000002536 stromal cell Anatomy 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 5
- 239000008177 pharmaceutical agent Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 101000577202 Homo sapiens Neurogenic locus notch homolog protein 3 Proteins 0.000 description 1
- 229940123309 Immune checkpoint modulator Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462073634P | 2014-10-31 | 2014-10-31 | |
| US62/073,634 | 2014-10-31 | ||
| US201562127172P | 2015-03-02 | 2015-03-02 | |
| US62/127,172 | 2015-03-02 | ||
| US201562192133P | 2015-07-14 | 2015-07-14 | |
| US62/192,133 | 2015-07-14 | ||
| US201562242567P | 2015-10-16 | 2015-10-16 | |
| US62/242,567 | 2015-10-16 | ||
| PCT/US2015/058327 WO2016070051A2 (en) | 2014-10-31 | 2015-10-30 | Combination therapy for treatment of disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537892A JP2017537892A (ja) | 2017-12-21 |
| JP2017537892A5 true JP2017537892A5 (enExample) | 2018-12-06 |
| JP6827415B2 JP6827415B2 (ja) | 2021-02-10 |
Family
ID=55858530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523286A Active JP6827415B2 (ja) | 2014-10-31 | 2015-10-30 | 疾患の処置のための併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20160176962A1 (enExample) |
| EP (1) | EP3212233B1 (enExample) |
| JP (1) | JP6827415B2 (enExample) |
| CN (1) | CN107530419B (enExample) |
| AU (1) | AU2015338974B2 (enExample) |
| CA (1) | CA2966042A1 (enExample) |
| DK (1) | DK3212233T3 (enExample) |
| ES (1) | ES2808153T3 (enExample) |
| MX (1) | MX382902B (enExample) |
| PT (1) | PT3212233T (enExample) |
| WO (1) | WO2016070051A2 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2488204E (pt) | 2009-10-16 | 2016-06-09 | Oncomed Pharm Inc | Combinação terapêutica e utilização de anticorpos antagonistas de dll4 e agentes anti-hipertensivos |
| PL2758073T3 (pl) | 2011-09-23 | 2019-04-30 | Oncomed Pharm Inc | Środki wiążące VEGF/DLL4 i ich zastosowania |
| WO2014055897A2 (en) * | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| US9789182B2 (en) * | 2012-10-23 | 2017-10-17 | Bristol-Myers Squibb Company | Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer |
| CN105339389B (zh) | 2013-05-02 | 2021-04-27 | 安奈普泰斯生物有限公司 | 针对程序性死亡-1(pd-1)的抗体 |
| LT3081576T (lt) | 2013-12-12 | 2019-10-25 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antikūnas, antigeną surišantis jo fragmentas ir jų medicininis pritaikomumas |
| CA2966042A1 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| WO2016073760A1 (en) | 2014-11-05 | 2016-05-12 | The Regents Of The University Of California | Methods for stratifying non-responders to therapies that block pd1/pdl1 axis |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CN108368170B (zh) | 2015-07-13 | 2022-04-15 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| ES2968074T3 (es) | 2015-09-23 | 2024-05-07 | Mereo Biopharma 5 Inc | Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino |
| EP3442528B1 (en) | 2016-04-12 | 2021-05-26 | Eli Lilly and Company | Combination therapy with notch and pi3k/mtor inhibitors for use in treating ovarian cancer |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) * | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI822521B (zh) * | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| US10688104B2 (en) * | 2016-05-20 | 2020-06-23 | Eli Lilly And Company | Combination therapy with Notch and PD-1 or PD-L1 inhibitors |
| CA3027121A1 (en) | 2016-06-10 | 2017-12-14 | Regeneron Pharmaceuticals, Inc. | Anti-gitr antibodies and uses thereof |
| WO2018009904A2 (en) * | 2016-07-08 | 2018-01-11 | Tumeh Paul C | Compositions and treatment methods for cancer immunotherapy |
| KR102899060B1 (ko) | 2016-07-14 | 2025-12-12 | 브리스톨-마이어스 스큅 컴퍼니 | Tim3에 대한 항체 및 그의 용도 |
| WO2018027524A1 (en) * | 2016-08-09 | 2018-02-15 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibody formulation |
| EP4342978A3 (en) | 2016-09-01 | 2024-07-03 | Chimera Bioengineering Inc. | Gold optimized car t-cells |
| WO2018049042A1 (en) * | 2016-09-07 | 2018-03-15 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating cancers by inhibiting estrogen signaling in myeloid-derived suppressor cells |
| CA3035262A1 (en) * | 2016-09-16 | 2018-03-22 | Tina Christine Lavranos | Antibody and checkpoint inhibitor combination therapy |
| WO2018085468A1 (en) | 2016-11-01 | 2018-05-11 | Anaptysbio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| US10780080B2 (en) * | 2016-11-23 | 2020-09-22 | Translational Drug Development, Llc | Benzamide and active compound compositions and methods of use |
| WO2018102769A1 (en) * | 2016-12-01 | 2018-06-07 | Bluelink Pharmaceuticals, Inc. | Treatment of cancer |
| FI3565844T3 (fi) | 2017-01-09 | 2023-05-09 | Tesaro Inc | Menetelmiä syövän hoitamiseksi anti-pd-1 -vasta-aineilla |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| PE20200303A1 (es) | 2017-05-24 | 2020-02-06 | Novartis Ag | Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer |
| EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
| WO2019023786A1 (en) * | 2017-08-01 | 2019-02-07 | University Health Network | COMBINED THERAPIES FOR THE INHIBITION OF TTK PROTEIN KINASE |
| CA3078605A1 (en) | 2017-08-28 | 2019-03-07 | Bristol-Myers Squibb Company | Tim-3 antagonists for the treatment and diagnosis of cancers |
| MA50564A (fr) | 2017-11-06 | 2020-09-16 | Hutchinson Fred Cancer Res | Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase |
| KR20250078626A (ko) | 2018-01-12 | 2025-06-02 | 브리스톨-마이어스 스큅 컴퍼니 | Tim3에 대한 항체 및 그의 용도 |
| EP3806870A4 (en) | 2018-02-13 | 2021-12-22 | Chimera Bioengineering, Inc. | COORDINATION OF GENE EXPRESSION USING RNA DESSTABILIZATION ELEMENTS |
| WO2019217250A1 (en) * | 2018-05-06 | 2019-11-14 | Ayala Pharmaceuticals Inc. | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof |
| CN108753833B (zh) * | 2018-05-28 | 2021-12-03 | 上海海洋大学 | 斑马鱼notch3基因突变体的制备方法 |
| US12378307B2 (en) * | 2018-11-16 | 2025-08-05 | The Brigham And Women's Hospital, Inc. | Antibodies blocking DLL4-mediated notch signalling |
| KR20220017937A (ko) * | 2019-06-05 | 2022-02-14 | 써던 리서취 인스티튜트 | 티아라빈- 및 티아라빈 전구약물-기반 치료 |
| WO2021034653A1 (en) | 2019-08-18 | 2021-02-25 | Chimera Bioengineering, Inc. | Combination therapy with gold controlled transgenes |
| JP7566923B2 (ja) | 2020-03-06 | 2024-10-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｇｉｔｒ抗体およびその使用 |
| WO2022125392A1 (en) * | 2020-12-09 | 2022-06-16 | Chimera Bioengineering, Inc. | Compositions and methods for activating t-cells |
| WO2022260968A1 (en) * | 2021-06-10 | 2022-12-15 | Chimera Bioengineering, Inc. | Compositions and methods for activating natural killer cells |
| EP4417619A4 (en) * | 2021-10-12 | 2025-12-03 | Palmira Biopharma Llc | NUCLEOTIDE SEQUENCE CODING FOR A FUSION PROTEIN |
| CN121263449A (zh) | 2023-03-21 | 2026-01-02 | 拜格拉夫55公司 | Cd19/cd38多特异性抗体 |
Family Cites Families (167)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| IL101728A (en) | 1991-05-03 | 2007-08-19 | Univ Yale | Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them |
| US5786158A (en) | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
| US20050112121A1 (en) | 1992-04-30 | 2005-05-26 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| DK0861261T3 (da) | 1995-06-28 | 2009-12-14 | Imp Cancer Res Tech | Nukleotid- og proteinsekvenser af hvirveldyrs-Delta-gener og fremgangsmåder baseret derpå |
| US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
| JPH09124697A (ja) | 1995-11-01 | 1997-05-13 | Toagosei Co Ltd | ペプチド及びモノクローナル抗体 |
| WO1997019172A1 (en) | 1995-11-17 | 1997-05-29 | Asahi Kasei Kogyo Kabushiki Kaisha | Differentiation-suppressive polypeptide |
| US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030180784A1 (en) | 1997-04-04 | 2003-09-25 | Millennium Pharmaceuticals, Inc. | Novel human Delta3 compositions and therapeutic and diagnostic uses therefor |
| US6121045A (en) | 1997-04-04 | 2000-09-19 | Millennium Biotherapeutics, Inc. | Human Delta3 nucleic acid molecules |
| US20060122373A1 (en) | 1997-04-04 | 2006-06-08 | Millennium Pharmaceuticals, Inc. | Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof |
| CA2285020A1 (en) | 1997-04-04 | 1998-10-15 | Millennium Biotherapeutics, Inc. | Novel human delta3 compositions and therapeutic and diagnostic uses therefor |
| ES2236634T3 (es) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US20070059302A1 (en) | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| ES2246069T3 (es) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| DK1004669T3 (da) | 1997-05-14 | 2007-08-27 | Asahi Chemical Ind | Hidtil ukendte differentieringsinhibitor |
| WO1998057621A1 (en) | 1997-06-18 | 1998-12-23 | The Trustees Of Columbia University In The City Ofnew York | Angiogenic modulation by notch signal transduction |
| US6004528A (en) | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
| AU4870599A (en) | 1998-07-27 | 2000-02-21 | Amgen, Inc. | Delta-related polypeptides |
| EP1185559A2 (en) | 1999-04-28 | 2002-03-13 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| CA2496312A1 (en) | 1999-12-01 | 2001-06-07 | Kevin P. Baker | Colon tumour marker pro4799 polypeptides and nucleic acids encoding the same |
| US20110131679A2 (en) | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| US20020028488A1 (en) | 2000-06-19 | 2002-03-07 | Sujay Singh | Transgenic avian species for making human and chimeric antibodies |
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| US6689744B2 (en) | 2000-09-22 | 2004-02-10 | Genentech, Inc. | Notch receptor agonists and uses |
| US7667004B2 (en) | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| JP2004537314A (ja) | 2001-07-25 | 2004-12-16 | ロランティス リミテッド | ノッチシグナル伝達モジュレーターを検出する方法 |
| ATE462006T1 (de) | 2001-08-01 | 2010-04-15 | Univ Bristol | Isoform des vegfs |
| AU2002339157A1 (en) | 2001-11-14 | 2003-05-26 | Lorantis Limited | Inhibitors of the notch signalling pathway for use in the treatment of cancer |
| CA2465304A1 (en) | 2001-11-14 | 2003-05-22 | Lorantis Limited | Composition comprising inhibitors of the notch signalling pathway for the modulation of the immune system |
| US20050137130A1 (en) | 2001-11-14 | 2005-06-23 | Bodmer Mark W. | Medical treatment |
| EP1461023A4 (en) | 2001-12-07 | 2005-08-31 | Univ Michigan | Prospective Identification and Characterization of Breast Cancer Strain Cells |
| AUPS054702A0 (en) * | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
| US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| GB0218879D0 (en) | 2002-08-14 | 2002-09-25 | Lorantis Ltd | Medical treatment |
| CA2497226A1 (en) | 2002-09-10 | 2004-03-25 | Lorantis Limited | Pharmaceutical compositions and medical treatments comprising notch ligand proteins |
| WO2004110490A2 (en) | 2003-06-06 | 2004-12-23 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitors for tumor regression |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
| US20050079184A1 (en) | 2003-08-08 | 2005-04-14 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| FR2859725B1 (fr) | 2003-09-16 | 2006-03-10 | Neovacs | Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine |
| AU2005254058A1 (en) | 2004-06-10 | 2005-12-29 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for the treatment of human cancer |
| CA2567738C (en) | 2004-06-15 | 2010-12-21 | F. Hoffmann-La Roche Ag | The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication |
| WO2006009809A2 (en) | 2004-06-18 | 2006-01-26 | Regeneron Pharmaceuticals, Inc. | Vegf inhibitors for the treatment of malignant pleural effusion |
| EP1615036B1 (en) | 2004-07-07 | 2007-09-19 | F.Hoffmann-La Roche Ag | Multimarker panel for diabetes type 1 and 2 |
| JP2008511337A (ja) | 2004-09-02 | 2008-04-17 | ジェネンテック・インコーポレーテッド | ヘテロ多量体分子 |
| US20080254031A1 (en) | 2004-09-09 | 2008-10-16 | Exonhit Therapeutics Sa | Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis |
| JP4958555B2 (ja) | 2004-09-22 | 2012-06-20 | 協和発酵キリン株式会社 | 安定化されたヒトＩｇＧ４抗体 |
| US8048418B2 (en) | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
| US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| NZ555216A (en) | 2004-11-10 | 2010-05-28 | Hubrecht Lab | Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation |
| EP1812064A4 (en) | 2004-11-19 | 2009-07-08 | Cornell Res Foundation Inc | USE OF VASCULAR ENDOTHEL GROWTH FACTOR RECEPTOR 1+ CELLS IN THE TREATMENT AND MONITORING OF CANCER AND SCREENING IN CHEMOTHERAPY |
| US7432107B2 (en) | 2005-01-24 | 2008-10-07 | Roche Diagnostics Operations, Inc. | Cardiac hormones for assessing cardiovascular risk |
| AU2006213856B2 (en) | 2005-02-11 | 2011-03-17 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a VEGF antagonist (VEGF trap) and an anti-hypertensive agent |
| CA2603408C (en) | 2005-03-31 | 2018-08-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| EP1868650B1 (en) | 2005-04-15 | 2018-10-03 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| CA2970873C (en) * | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR20080026562A (ko) | 2005-06-02 | 2008-03-25 | 갤럭시 바이오테크, 엘엘씨 | 항체를 이용한 뇌종양 치료 방법 |
| EA019344B1 (ru) * | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| CA2615636A1 (en) | 2005-08-12 | 2007-02-22 | Regeneron Pharmaceuticals, Inc. | Treatment of diseases by subcutaneous administration of a vegf antagonist |
| CA2621226A1 (en) | 2005-09-01 | 2007-03-08 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| US7906116B2 (en) | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
| AU2006308847C1 (en) | 2005-10-31 | 2012-05-10 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
| JP5489465B2 (ja) | 2005-12-16 | 2014-05-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法 |
| US20090221549A1 (en) | 2006-02-17 | 2009-09-03 | Gilead Colorado, Inc. | Antihypertensive therapy |
| US8133857B2 (en) | 2006-03-07 | 2012-03-13 | The Brigham and Women's FHospital, Inc. | NOTCH inhibition in the treatment of atherosclerosis |
| WO2011053822A2 (en) | 2009-11-01 | 2011-05-05 | The Brigham And Women's Hospital, Inc. | Notch inhibition in the treatment and prevention of obesity and metabolic syndrome |
| US7354582B2 (en) | 2006-03-10 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Use of VEGF antagonists for the treatment of malignant gliomas |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| BRPI0710411A2 (pt) | 2006-06-06 | 2012-04-10 | Genentch Inc Empresa Americana | Métodos para tratar um tumor, para tratar uma condição patológica associada à angiogênese, para estimular a proliferação celular endotelial, para reduzir ou inibir a diferenciação celular endotelial, para reduzir ou inibir o desenvolvimento arterial, para reduzir ou inibir a perfusão vascular tumoral para aumentar a eficácia de um agente anti-angiogênico, usos de um antagonista de dll4 e uso de um agonisra de dll4 |
| NZ572177A (en) * | 2006-06-06 | 2012-02-24 | Genentech Inc | Anti-dll4 antibodies and methods using same |
| JP2009539403A (ja) | 2006-06-13 | 2009-11-19 | オンコメッド ファーマシューティカルズ インコーポレイテッド | 癌を診断および処置するための組成物および方法 |
| US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
| JP5529536B2 (ja) | 2006-08-07 | 2014-06-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 虚血性障害又は血管不全の治療におけるＤｌｌ４アンタゴニストの使用 |
| EP2059533B1 (en) | 2006-08-30 | 2012-11-14 | Genentech, Inc. | Multispecific antibodies |
| EP2066694B1 (en) | 2006-09-29 | 2015-11-04 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| CN101583624B (zh) * | 2006-09-29 | 2012-11-21 | 昂考梅德药品有限公司 | 用于诊断和治疗癌症的组合物及其用途 |
| CA2666974A1 (en) | 2006-10-20 | 2008-11-06 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| WO2008070350A2 (en) | 2006-10-27 | 2008-06-12 | The Board Of Regents Of The University Of Texas System | Methods and compositions related to wrapping of dehydrons |
| US20100166746A1 (en) | 2006-12-04 | 2010-07-01 | Medlmmune Way | High potency recombinant antibodies, methods for producing them and use in cancer therapy |
| KR101320198B1 (ko) | 2006-12-11 | 2013-10-30 | 제넨테크, 인크. | 신생물의 치료를 위한 조성물 및 방법 |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| CA2671734A1 (en) | 2006-12-19 | 2008-06-26 | Genentech, Inc. | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
| WO2008079326A2 (en) | 2006-12-20 | 2008-07-03 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| EP2125013A4 (en) | 2007-01-26 | 2010-04-07 | Bioinvent Int Ab | DLL4 SIGNALING INHIBITOR AND ITS USES |
| RU2009144972A (ru) | 2007-05-04 | 2011-06-10 | Айронвуд Фармасьютикалз, Инк. (Us) | Композиции и способы лечения нарушений, ассоциированных с задержкой соли или жидкости |
| GB0709333D0 (en) | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| JP2011500086A (ja) | 2007-10-22 | 2011-01-06 | シェーリング コーポレイション | 完全ヒト抗ｖｅｇｆ抗体および使用方法 |
| AU2008315414A1 (en) | 2007-10-25 | 2009-04-30 | Philogene, Inc. | Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (VEGF) |
| AR069501A1 (es) | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
| WO2009075565A1 (en) | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Methods for controlling vasculogenesis |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
| CN102056945A (zh) | 2008-04-07 | 2011-05-11 | 埃博灵克斯股份有限公司 | 针对Notch途径的单可变结构域 |
| EP2282769A4 (en) | 2008-04-29 | 2012-04-25 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| BRPI0914007A2 (pt) * | 2008-07-08 | 2015-11-17 | Oncomed Pharm Inc | anatagonistas e agentes de ligação de notch e métodos para uso dos mesmos |
| WO2010010155A1 (en) | 2008-07-23 | 2010-01-28 | F. Hoffmann-La Roche Ag | Monitoring anti-angiogenesis therapy |
| EP2321651B1 (en) | 2008-07-23 | 2017-08-23 | F. Hoffmann-La Roche AG | Identification of subjects being susceptible to anti-angiogenesis therapy |
| EA201170375A1 (ru) * | 2008-08-25 | 2012-03-30 | Эмплиммьюн, Инк. | Антагонисты pd-1 и способы их применения |
| RU2581962C2 (ru) * | 2008-09-19 | 2016-04-20 | Медиммун Ллк | Нацеленные средства связывания, направленные на dll4, и их применение |
| WO2010054007A1 (en) | 2008-11-07 | 2010-05-14 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| PE20120415A1 (es) | 2008-12-12 | 2012-05-09 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| JP2012524083A (ja) | 2009-04-20 | 2012-10-11 | ジェネンテック， インコーポレイテッド | アジュバント癌治療 |
| WO2010124009A2 (en) | 2009-04-21 | 2010-10-28 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| TWI513465B (zh) | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法 |
| MX2011013455A (es) | 2009-07-08 | 2012-02-13 | Amgen Inc | Diseño de moleculas de fc de anticuerpo estables y libres de agregacion a traves del diseño de la interfase del dominio de ch3. |
| TWI465250B (zh) | 2009-08-29 | 2014-12-21 | Abbvie Inc | 治療用之ｄｌｌ４結合蛋白質 |
| CN102612524A (zh) | 2009-09-01 | 2012-07-25 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
| US20110172398A1 (en) | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
| PT2488204E (pt) | 2009-10-16 | 2016-06-09 | Oncomed Pharm Inc | Combinação terapêutica e utilização de anticorpos antagonistas de dll4 e agentes anti-hipertensivos |
| WO2011047442A1 (en) | 2009-10-23 | 2011-04-28 | Garvan Institute Of Medical Research | Modified variable domain molecules and methods for producing and using same |
| WO2011068840A1 (en) | 2009-12-01 | 2011-06-09 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancers comprising k-ras mutations |
| ES2561102T3 (es) * | 2010-01-13 | 2016-02-24 | Oncomed Pharmaceuticals, Inc. | Agentes de unión a Notch1 y procedimientos de uso de los mismos |
| JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| KR20120117931A (ko) | 2010-02-12 | 2012-10-24 | 온코메드 파마슈티칼스, 인크. | 폴리펩타이드를 발현하는 세포를 확인 및 분리하는 방법 |
| CN105037543B (zh) | 2010-03-02 | 2020-11-03 | Abbvie 公司 | 治疗性dll4结合蛋白 |
| PT2609118T (pt) | 2010-08-23 | 2017-03-22 | Univ Texas | Anticorpos anti-ox40 e métodos de utilização dos mesmos |
| US8551479B2 (en) * | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| WO2012068098A1 (en) | 2010-11-15 | 2012-05-24 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with dll4 antagonists |
| WO2012073987A1 (ja) * | 2010-12-01 | 2012-06-07 | キッコーマン株式会社 | 大腸菌形質転換体、それを用いたフラビン結合型グルコースデヒドロゲナーゼの製造方法、および、変異型フラビン結合型グルコースデヒドロゲナーゼ |
| TWI530489B (zh) * | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯二氮呯酮化合物 |
| US8685401B2 (en) | 2011-06-17 | 2014-04-01 | Adrian Harris | Methods of enhancing the response to radiation in tumor therapy using anti-DLL4 antibodies |
| PL2758073T3 (pl) * | 2011-09-23 | 2019-04-30 | Oncomed Pharm Inc | Środki wiążące VEGF/DLL4 i ich zastosowania |
| JP2015505668A (ja) * | 2011-11-16 | 2015-02-26 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヒトｎｏｔｃｈ受容体変異およびその使用 |
| CA2863564A1 (en) | 2012-02-03 | 2013-08-08 | Medimmune Limited | Process for reducing antibody aggregate levels and antibodies produced thereby |
| KR102418979B1 (ko) * | 2012-05-15 | 2022-07-11 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| US20130323266A1 (en) * | 2012-05-16 | 2013-12-05 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with notch2/3 antibodies |
| AR092325A1 (es) | 2012-05-31 | 2015-04-15 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
| CA2874979A1 (en) | 2012-05-31 | 2014-04-24 | Edwige Gros | Antigen binding proteins that bind dll-4 |
| KR101535341B1 (ko) | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
| NZ702201A (en) | 2012-07-13 | 2018-01-26 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| MX2015003894A (es) | 2012-09-28 | 2015-07-17 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 agentes anti-vegf. |
| WO2014055897A2 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| AU2013337811A1 (en) | 2012-10-31 | 2015-05-14 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
| SG11201503412RA (en) | 2012-11-01 | 2015-05-28 | Abbvie Inc | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
| AR093445A1 (es) | 2012-11-14 | 2015-06-10 | Regeneron Pharma | Metodos para tratar el cancer de ovario con antagonistas de dll4 |
| CN105339389B (zh) | 2013-05-02 | 2021-04-27 | 安奈普泰斯生物有限公司 | 针对程序性死亡-1(pd-1)的抗体 |
| WO2015130751A1 (en) | 2014-02-26 | 2015-09-03 | Medimmune, Llc | Methods of treatment with dll4 antagonists |
| KR102399005B1 (ko) * | 2014-03-11 | 2022-05-17 | 리제너론 파마슈티칼스 인코포레이티드 | 항-egfrviii 항체 및 그것의 용도 |
| EP3166627A1 (en) | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Notch pathway inhibition |
| CA2966042A1 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| ES2968074T3 (es) * | 2015-09-23 | 2024-05-07 | Mereo Biopharma 5 Inc | Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino |
| WO2020012447A1 (en) | 2018-07-13 | 2020-01-16 | Composite Interceptive Med-Science Laboratories Private Limited | Polyherbal formulation and method for production thereof |
-
2015
- 2015-10-30 CA CA2966042A patent/CA2966042A1/en active Pending
- 2015-10-30 PT PT158561001T patent/PT3212233T/pt unknown
- 2015-10-30 ES ES15856100T patent/ES2808153T3/es active Active
- 2015-10-30 CN CN201580068724.2A patent/CN107530419B/zh active Active
- 2015-10-30 EP EP15856100.1A patent/EP3212233B1/en active Active
- 2015-10-30 AU AU2015338974A patent/AU2015338974B2/en active Active
- 2015-10-30 US US14/928,271 patent/US20160176962A1/en not_active Abandoned
- 2015-10-30 DK DK15856100.1T patent/DK3212233T3/da active
- 2015-10-30 WO PCT/US2015/058327 patent/WO2016070051A2/en not_active Ceased
- 2015-10-30 MX MX2017005258A patent/MX382902B/es unknown
- 2015-10-30 JP JP2017523286A patent/JP6827415B2/ja active Active
-
2018
- 2018-02-06 US US15/889,532 patent/US11046760B2/en active Active
-
2021
- 2021-05-26 US US17/330,716 patent/US20210403553A1/en not_active Abandoned
-
2024
- 2024-06-28 US US18/758,255 patent/US20250179169A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537892A5 (enExample) | ||
| Yonezawa et al. | Boosting cancer immunotherapy with anti-CD137 antibody therapy | |
| WO2016070051A4 (en) | Combination therapy for treatment of disease | |
| Aranda et al. | Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy | |
| CN107847587B (zh) | Cd30×cd16抗体与pd-1拮抗剂的联合药物 | |
| AU2014351308B2 (en) | Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy | |
| US20230111786A1 (en) | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent | |
| EP2970473B1 (en) | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use | |
| JP2016525117A5 (enExample) | ||
| JP2020503273A5 (enExample) | ||
| JP2019513725A5 (enExample) | ||
| JP2015508816A5 (enExample) | ||
| JP2020522495A5 (enExample) | ||
| JP2017532952A5 (enExample) | ||
| JP2021529741A (ja) | がん治療 | |
| JP2017534633A5 (enExample) | ||
| WO2016126781A4 (en) | Tnfrsf-binding agents and uses thereof | |
| JP2020500181A5 (enExample) | ||
| Patnaik et al. | Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia/Ib trial | |
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| JP2018503365A5 (enExample) | ||
| JP2017500057A5 (enExample) | ||
| KR20220007593A (ko) | 암 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용 | |
| JP2015529641A5 (enExample) | ||
| JP2015536933A5 (enExample) |